CIDRAP Details Latest Studies -- In Mpox Abatement -- For Pregnant Women, Infants and Toddlers. Good News!

The vaccine has long shown efficacy in other -pox viral vectors, and it has worked well, in adult Mpox Clade 1b outbreaks. So, there is reason to believe it should work here, in the most vulnerable population/cohorts -- infants, toddlers and pregnant women.

We will keep you posted, but here's the latest, via the estimable CIDRAP -- on global public health/viral disease matters:

. . .Bavarian Nordic President and CEO Paul Chaplin, PhD, said, "These new studies will fill the gap by providing important data about the use of MVA-BN in infants and pregnant women, and we applaud the study partners as well as the funding partners, EDCTP3 and CEPI [Coalition for Epidemic Preparedness Innovations] for supporting this important work, which could help support a label expansion for MVA-BN to include the most vulnerable populations."

Both studies are part of the PregInPoxVac research project, led by the University of Antwerp and the University of Kinshasa.

In addition, Bavarian Nordic is sponsoring a trial of Jynneos in children aged 2 to 11 years old, which has received funding support from CEPI. It expects results from this trial later this year. . . .

Now you know. Onward, resolutely -- eleven on. Grin.

नमस्ते